EXCLUSIVE: HemoGenyx are creating blood cancer treatments with US$9 billion market potential
#HEMO are a London-listed, US-based biotech company developing two revolutionary blood cancer treatments. CDX antibodies are intended to remove the need for chemo and radiation before a bone...